COVID-19 Medicines in Pharmacogenomics
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: closed (20 February 2024) | Viewed by 723
Special Issue Editors
Interests: drug repurposing; computer-aided drug and vaccine design; genomic biomarkers; nanomedicine; personalized medicine
Interests: biomedical informatics; computational genomics; machine learning and drug design; precision medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmacogenomics may allow extreme drug response phenotypes observed in the clinic to be used to study the molecular mechanisms of drug safety and efficacy in individuals. Pharmacogenomics has begun to move to the center stage of COVID-19 drug design and development, including repurposed drugs and different vaccine platforms that are being used for COVID-19. Predefined drug (i.e., authorized for emergency use) safety and efficacy can be detected more effectively through pharmacogenomics during and after clinical trials. Personalized medicines are required for subpopulations, and they are different from HLA genotypes and other genetic variations because studies have proven that a single medicine does not work for the entire population. Thus, pharmacogenomics-based biomarkers would offer a conceptual and practical steering wheel and prospects to design clinical trials for new COVID-19 medicines or precision medicine. In addition, pharmacogenomics variations in drug targets and pharmacokinetics can potentially reduce the costs and duration of clinical trials. A repurposing strategy might be more effective and successful if pharmacogenetic interventions are considered. This Special Issue invites potential manuscripts that cover topics including pharmacogenomics, biomarkers, drug repurposing, drug–target interactions, drug–gene interactions, and advances in artificial intelligence in pharmacogenomics related to COVID-19 and coronavirus-mediated disease.
Dr. Satyavani Kaliamurthi
Dr. Gurudeeban Selvaraj
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- COVID-19
- clinical trials
- drug repurposing
- drug–target interaction
- drug-metabolizing enzymes
- drug–gene interaction
- drug–herb interaction
- drug safety and efficacy
- machine learning in pharmacogenomics
